Propanc Biopharma (PPCB) News Today $1.78 -0.05 (-2.73%) As of 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisChartEarningsHeadlinesSEC FilingsShort InterestBuy This Stock PPCB Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent October 2025 September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 Time Period Propanc Biopharma (OTCMKTS:PPCB) Stock Price Down 2.6% - Time to Sell?October 9, 2025 | americanbankingnews.comPropanc Biopharma reports total assets of $19.6M as of June 30October 7, 2025 | msn.comPropanc Reports End of Fiscal Year Highlights and Outlines Therapeutic Development & $100M+ Digital Asset Treasury StrategyOctober 7, 2025 | globenewswire.comCrypto and Cancer: How Biotech’s New Strategy Is Turning HeadsSeptember 22, 2025 | theglobeandmail.comPropanc Biopharma receives certificate of grant from USPTOSeptember 17, 2025 | msn.comPropanc Biopharma Receives Certificate of Grant for “Proenzyme Composition” Patent from US Patent & Trademark OfficeSeptember 17, 2025 | globenewswire.comPropanc Biopharma Announces Plan to Acquire $100 Million of EthereumSeptember 2, 2025 | globenewswire.comD. Boral Capital Acted as Lead Bookrunner to Propanc Biopharma, Inc. in Connection with its $4,000,000 UplistingAugust 28, 2025 | finanznachrichten.deD. Boral Capital Acted as Lead Bookrunner to Propanc Biopharma, Inc. (Nasdaq:PPCB) in Connection with its $4,000,000 UplistingAugust 28, 2025 | finance.yahoo.comPropanc Biopharma raises $4 million in Nasdaq debut, plans cancer trialsAugust 26, 2025 | investing.comPropanc Biopharma Provides Shareholder UpdateAugust 25, 2025 | globenewswire.comPropanc Biopharma, Inc.: Propanc Biopharma Announces Closing of Public Offering and Uplisting to NASDAQAugust 20, 2025 | finanznachrichten.dePropanc Biopharma Announces Closing of Public Offering and Uplisting to NASDAQAugust 19, 2025 | globenewswire.comWhy Propanc stock Is Tumbling In Premarket TodayAugust 19, 2025 | msn.comThe Next Wave of Cancer Innovation: How Breakthrough Therapies Are Redefining Treatment ParadigmsAugust 18, 2025 | theglobeandmail.comPropanc Biopharma IncAugust 17, 2025 | cnn.comPropanc Biopharma opens at $4.00 in Nasdaq uplistingAugust 15, 2025 | msn.comPropanc Biopharma, Inc.: Propanc Biopharma Announces Nasdaq Uplisting and Pricing of $4 Million Public OfferingAugust 15, 2025 | finanznachrichten.dePropanc Biopharma prices $4M stock offeringAugust 15, 2025 | msn.comPropanc Biopharma Announces Nasdaq Uplisting and Pricing of $4 Million Public OfferingAugust 14, 2025 | globenewswire.comPropanc Biopharma 1M share Secondary; price range $4.00-$6.00August 14, 2025 | msn.comPropanc Biopharma Appoints New Chief Financial OfficerAugust 14, 2025 | msn.comPropanc Biopharma Issues Promissory Note for CapitalJune 2, 2025 | tipranks.comPropanc Biopharma (OTCMKTS:PPCB) Stock Price Down 53.7% - Should You Sell?February 26, 2025 | marketbeat.comPropanc Biopharma (OTCMKTS:PPCB) Trading Up 108.3% - Still a Buy?January 30, 2025 | marketbeat.comPropanc Biopharma Inc (PPCB)August 21, 2024 | investing.comPropanc Biopharma Receives Notice of Allowance for "Proenzyme Composition" Patent in North AmericaAugust 14, 2024 | finance.yahoo.comVTXB Vortex Brands Co.May 29, 2024 | seekingalpha.comPropanc Biopharma, Inc. (PPCB)May 29, 2024 | finance.yahoo.comPropanc Biopharma Receives Certificate of Grant for "Composition of Proenzymes for Cancer Treatment" Patent from European Patent OfficeApril 16, 2024 | finance.yahoo.comPropanc Biopharma's CEO Shares Views on Revolutionizing Cancer Treatment: An Inside Look at Drug Development & Strategic FinancingApril 10, 2024 | stockhouse.comPropanc Biopharma’s CEO Shares Views on Revolutionizing Cancer Treatment: An Inside Look at Drug Development & Strategic FinancingApril 8, 2024 | finance.yahoo.comPropanc Biopharma to Host Corporate Update Call Highlighting Recent Progress and Positive Results from Compassionate Use StudyFebruary 22, 2024 | finance.yahoo.comPropanc Biopharma Receives Certificate of Grant for PRP Foundation Patent from Canadian Intellectual Property OfficeJanuary 16, 2024 | finance.yahoo.comPropanc Biopharma Engages Boutique Advisory Firm to Identify Strategic Investment OpportunitiesDecember 18, 2023 | finance.yahoo.comPropanc Biopharma’s Joint Research Partner Pushing Boundaries to Circumvent Chemotherapy Resistance Using PRPDecember 13, 2023 | finance.yahoo.comJames Nathanielsz, CEO of Propanc Biopharma, Inc., is Featured in an Interview With SmallCapsDailyDecember 12, 2023 | finance.yahoo.comPropanc Biopharma, Inc.: Propanc Biopharma Confirms PRP Enhances Chemosensitivity and Alters Tumor Microenvironment of Pancreatic Tumor CellsNovember 7, 2023 | finanznachrichten.dePropanc Biopharma Confirms PRP Enhances Chemosensitivity and Alters Tumor Microenvironment of Pancreatic Tumor CellsNovember 7, 2023 | finance.yahoo.comPropanc Biopharma Targets Site of First-In-Human Study for PRP at the Peter Mac Cancer Center, Melbourne, AustraliaAugust 15, 2023 | finance.yahoo.comPropanc Biopharma’s Clinical Candidate PRP Targeting Pancreatic Cancer Market Forecast to Reach $6.93 Billion by 2030July 26, 2023 | finance.yahoo.comPropanc Biopharma Peer Reviewed Scientific Article Reaches 3,000 ReadsJuly 13, 2023 | finance.yahoo.comPropanc Biopharma Produces Synthetic Recombinant Proenzymes for Cancer Therapy Targeting Advanced Solid TumorsJuly 5, 2023 | finance.yahoo.comPPCB - Propanc Biopharma, Inc.June 30, 2023 | sg.finance.yahoo.comPROPANC BIOPHARMA INC (PPCB) stock forecast and price targetJune 28, 2023 | finance.yahoo.comPropanc Biopharma’s Intellectual Property Portfolio Makes Important Advancements in EuropeMay 25, 2023 | finance.yahoo.comPropanc Biopharma’s Intellectual Property Portfolio Achieves Significant Milestones in North AmericaMay 23, 2023 | finance.yahoo.comPropanc Biopharma Announces Reverse Stock SplitMay 23, 2023 | finance.yahoo.comPropanc Biopharma Announces That PRP Suppresses TGF-β Pathway & Tumor Microenvironment in Pancreatic CancerMarch 28, 2023 | finance.yahoo.comPropanc Biopharma Confirms PRP Exerts Significant Effects Against Chemoresistant Pancreatic Tumor CellsMarch 16, 2023 | finance.yahoo.com Get Propanc Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for PPCB and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. PPCB Media Mentions By Week PPCB Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. PPCB News Sentiment▼0.120.75▲Average Medical News Sentiment PPCB News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. PPCB Articles This Week▼10▲PPCB Articles Average Week Get the Latest News and Ratings for PPCB and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Propanc Biopharma and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies Kalaris Therapeutics News Equillium News Immix Biopharma News Assertio News Unicycive Therapeutics News Werewolf Therapeutics News Invizyne Technologies News Avenir Wellness Solutions News Vaxart News XBiotech News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (OTCMKTS:PPCB) was last updated on 10/14/2025 by MarketBeat.com Staff From Our PartnersURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredREVEALED: Something Big Happening Behind White House DoorsWhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredBuy this stock before Tesla’s November 6 announcementThe End of Tesla? "Hold onto your Tesla stock." That's the message insiders at Tesla have been giving staff...Altimetry | SponsoredWhat the hell is going on, America?America’s $37.5 trillion debt spiral, soaring deficits, and repeated credit downgrades are exactly what Porter...Porter & Company | SponsoredNvidia’s slow death marchEric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredOptions Pro Reveals His #1 Retirement Income TradeIf you want a way to generate consistent market income without chasing volatile AI stocks or complex crypto tr...Base Camp Trading | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Propanc Biopharma Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Propanc Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
